Martin J I Andrews

Title: Martin J I Andrews: Innovator in p21 Peptides

Introduction

Martin J I Andrews is a notable inventor based in Dundee, GB. He has made significant contributions to the field of biochemistry, particularly through his work on p21 derived peptides. His innovative approach has led to advancements in the inhibition of CDK/cyclin complexes, which are crucial in cell cycle regulation.

Latest Patents

Andrews holds a patent for p21 peptides, which are capable of inhibiting CDK/cyclin complexes, specifically targeting cyclins A or E/CDK2. The invention focuses on modifying the interaction of these peptides with their substrates. The peptides are derived from the C-terminal region of p21 and exhibit selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Notably, variants of these peptides, particularly those involving certain alanine replacements, have shown to be particularly potent. He has 1 patent to his name.

Career Highlights

Andrews is associated with Cyclacel Limited, a company that focuses on developing innovative cancer therapies. His work at Cyclacel has allowed him to contribute to the advancement of treatments that target critical pathways in cancer cell proliferation.

Collaborations

Andrews has collaborated with notable colleagues, including Daniella I Zheleva and Peter Martin Fischer. These collaborations have likely enriched his research and contributed to the success of his innovations.

Conclusion

Martin J I Andrews is a distinguished inventor whose work on p21 peptides has the potential to impact cancer treatment significantly. His innovative contributions and collaborations highlight his role in advancing biochemistry and therapeutic development.